Navigation Links
Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
Date:4/30/2008

OMAHA, Neb., April 30 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a global genetic analysis and services company, today announced the National Cancer Institute had approved a proposal to perform mutational analysis and sequencing of the mitochondrial genes in the NCI 60 cancer cell line panel.

Mitochondrial damage is increasingly recognized as an early warning signal in several different types of cancer. This is the first comprehensive evaluation of the mitochondrial genome in the NCI 60 panel. The data from this study will be a valuable tool for integrating mitochondrial genomics with other data derived from the NCI 60 panel.

"Tens of thousands of compounds have been tested against the NCI 60 cell lines in the NCI's pharmacological database of cancer drugs," chief scientific officer Dr. Eric Kaldjian described. "This collaboration makes it possible to test whether in vitro responses to anti-cancer agents are linked to alterations in the mitochondrial genome and can be detected with our sensitive mutation detection technology."

Chief executive officer Craig Tuttle remarked, "Over the last 2 years, we have grown our laboratory services business focusing on diseases associated with mitochondrial DNA. As we learn more about the mitochondria and its role in disease, we are finding that mitochondrial mutation testing can provide diagnostic insights earlier in the disease process giving physicians early warning signals they can use to monitor at risk patients or even begin therapy. This study is an important milestone for the company and will further validate our leadership in the analysis of the mitochondrial genome in disease. The NCI 60 panel study further demonstrates Transgenomic's expertise in the evolving area of diagnostic testing for mitochondrial mutations."

About Transgenomic:

Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitiv
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
3. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
4. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
5. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... Company (NYSE: PG ) today announced that three ... (SEAP). The new members are: Caroline Hermans, ... Howard Frumkin – Dean, School of the Public Health at ... California Environmental Protection Agency "With key ...
... Fujirebio Diagnostics, Inc., today announced that the U.S. Food and ... CYFRA 21-1™ EIA assay to monitor disease progression during the ... is the first biomarker assay kit to be cleared by ... cancer. "The clearance of the CYFRA 21-1 assay ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer 2
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Unlike children, the vast ... on their plate at mealtime, according to a new study. ... the world -- not just Americans, researchers from Cornell University ... to lose weight or improve their eating habits make better ... going into your stomach," researcher Brian Wansink, director of ...
(Date:7/25/2014)... Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ... recognizes and attacks invading cancer cells. Tumors protect themselves ... as normal, even while cancer cells are dividing and ... review article published this week in WIREs Nanomedicine ... ability to fight tumors. Nanoparticles are too small ...
(Date:7/25/2014)... 2014 Innerspire, LLC ( http://www.innerspire.com ) ... as a Creative Enrollment Specialist. In this role, Greg ... as well as his accomplished design skills to further ... and to service the creative marketing needs ... work with small business owners and individuals looking to ...
(Date:7/25/2014)... July 25, 2014 “You have a brain ... 500 people and their loved ones across the U.S. every ... brain tumor diagnosis is typically met with confusion and uncertainty ... and difficult vocabulary, and make critical decisions about a course ... diagnosis is accompanied by a sense of isolation and a ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Progress in ... in a new era of promising brain tumor treatments, ... Medical School, director of the Center for Neuro-Oncology, Dana-Farber ... (ABTA) annual Patient and Family Conference in Chicago, July ... science and new technology are impacting the development of ...
Breaking Medicine News(10 mins):Health News:Most Adults Are Members of 'Clean Plate Club' 2Health News:Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4
... N.M., April 15 Civility Mutual, based in,Santa ... and only membership,organization to offer education, training and ... residency directors with the,educational tools and assessments their ... the ACGME Outcomes Project., "Civility in health ...
... Utrecht, The Netherlands April 15, 2008 ... 60 percent increased risk of developing pneumonia compared ... first week following prescription and decreases gradually thereafter. ... American Geriatrics Society. , Antipsychotic drugs are frequently ...
... HUNTSVILLE, Ala., April 15 Open Biosystems, ... science research,tools for drug discovery, today announced ... pools for multiplexed RNAi screens. This,novel offering ... and,the ability to rapidly screen through thousands ...
... 15 /Xinhua-PRNewswire-FirstCall/ -- CNinsure,Inc. CISG, a leading ... China, today announced the signing of an ... Co., Ltd ("Minsheng Life,Insurance")., According to ... with Minsheng Life Insurance at both the ...
... April 15, 2008 -- Results of a phase ... high-dose, high-frequency subcutaneous Rebif (interferon beta-1a) provide clinical evidence ... to 30 months of continued therapy in patients with ... in the April 2008 issue of the Current Medical ...
... practical for treating human diseases, researchers must master the ... The Childrens Hospital of Philadelphia have advanced delivery techniques ... to a variety of gene therapy vectors and can ... at a disease site. , In an animal study, ...
Cached Medicine News:Health News:New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements 2Health News:Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 3Health News:Study shows that high-dose, high-frequency interferon produces no additional benefit 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 3
... for this age group?, ,Babies and young ... of an MDI. , ,Dry powder devices ... achieve efficiency. , ,Traditional nebulizers have high ... often used for this age group are inefficient ...
... Compact Compressor is for active patients who ... and everywhere. The compressor is small and ... optionsworldwide AC compatibility (100 to 240V), 12 ... the freedom to take aerosol treatments away ...
... Compact sporty design and ... XL the product of choice ... and performance. The CompAir XL ... cord storage compartment and a ...
... The 50 psi MaxiCompressor, ... designed to run 24 hours ... week. It features a tamper-proof ... against unintentional increases or decreases ...
Medicine Products: